Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

@article{Hsiao2013RiskOB,
  title={Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.},
  author={Fei-Yuan Hsiao and P H Hsieh and W F Huang and Y Tsai and C. Joe Gau},
  journal={Drug safety},
  year={2013},
  volume={36 8},
  pages={643-9}
}
BACKGROUND Evidence has emerged that pioglitazone may increase the risk of bladder cancer, but the association has not been confirmed. This potential risk also has not been evaluated in users of rosiglitazone. OBJECTIVE Using Taiwan’s National Health Insurance Research Database (NHIRD), this large population-based nested case–control study was conducted to explore the relationship between the use of rosiglitazone or pioglitazone and risk of bladder cancer in diabetic patients. METHODS We… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

A review on thiazolidinediones and bladder cancer in human studies.

Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews • 2014
View 9 Excerpts
Highly Influenced

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis

Diabetes therapy : research, treatment and education of diabetes and related disorders • 2017
View 2 Excerpts

Similar Papers

Loading similar papers…